Significant Increase in Salivary Substance P Level after a Single Oral Dose of Cevimeline in Humans

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left" rowspan="2">Drugs</td><td align="center" colspan="3">AUC<svg height="7.8249998" id="M27" style="vertical-align:-3.3907pt" version="1.1" viewbox="0 0 30.0875 7.8249998" width="30.0875" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.012,-0,0,-.012,.062,7.612)"><path d="M241 635q53 0 94 -28.5t63.5 -76t33.5 -102.5t11 -116q0 -58 -11 -112.5t-34 -103.5t-63.5 -78.5t-94.5 -29.5t-95 28t-64.5 75t-34.5 102.5t-11 118.5q0 58 11.5 112.5t34.5 103t64.5 78t95.5 29.5zM238 602q-32 0 -55.5 -25t-35.5 -68t-17.5 -91t-5.5 -105
q0 -76 10 -138.5t37 -107.5t69 -45q32 0 55.5 25t35.5 68.5t17.5 91.5t5.5 105t-5.5 105.5t-18 92t-36 68t-56.5 24.5z" id="x30"></path></g>
<g transform="matrix(.012,-0,0,-.012,5.775,7.612)"><path d="M300 253l-14 -55h-229l14 55h229z" id="x2D"></path></g><g transform="matrix(.012,-0,0,-.012,8.036,7.612)"><path d="M300 253l-14 -55h-229l14 55h229z" id="x2D"></path></g>
<g transform="matrix(.012,-0,0,-.012,12.263,7.612)"><path d="M412 140l28 -9q0 -2 -35 -131h-373v23q112 112 161 170q59 70 92 127t33 115q0 63 -31 98t-86 35q-75 0 -137 -93l-22 20l57 81q55 59 135 59q69 0 118.5 -46.5t49.5 -122.5q0 -62 -29.5 -114t-102.5 -130l-141 -149h186q42 0 58.5 10.5t38.5 56.5z" id="x32"></path></g><g transform="matrix(.012,-0,0,-.012,17.974,7.612)"><path d="M456 178h-96v-72q0 -51 12.5 -62.5t72.5 -16.5v-27h-256v27q65 5 78 17t13 62v72h-260v28q182 271 300 426h40v-407h96v-47zM280 225v295h-2q-107 -148 -196 -295h198z" id="x34"></path></g><g transform="matrix(.012,-0,0,-.012,23.685,7.612)"><path d="M241 635q53 0 94 -28.5t63.5 -76t33.5 -102.5t11 -116q0 -58 -11 -112.5t-34 -103.5t-63.5 -78.5t-94.5 -29.5t-95 28t-64.5 75t-34.5 102.5t-11 118.5q0 58 11.5 112.5t34.5 103t64.5 78t95.5 29.5zM238 602q-32 0 -55.5 -25t-35.5 -68t-17.5 -91t-5.5 -105
q0 -76 10 -138.5t37 -107.5t69 -45q32 0 55.5 25t35.5 68.5t17.5 91.5t5.5 105t-5.5 105.5t-18 92t-36 68t-56.5 24.5z" id="x30"></path></g>
</svg> in plasma (pg min/mL)</td></tr><tr class="thead"><td align="center">SP</td><td align="center">CGRP</td><td align="center">VIP</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">Cevimeline</td><td align="center">453.4 ± 343.6</td><td align="center">2518.0 ± 1841.0</td><td align="center">295.1 ± 210.4</td></tr><tr><td align="left">Placebo</td><td align="center">445.3 ± 316.2</td><td align="center">2640.4 ± 1936.1</td><td align="center">398.4 ± 189.3</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>Data are expressed as mean ± SD.<br/></td></tr></table>

Total amounts of substance-P- (SP-), calcitonin-gene-related-peptide- (CGRP-), and vasoactive-intestinal-polypeptide-(VIP-) like immunoreactive substance in plasma released after administration of cevimeline or placebo to 7 healthy volunteers.

International Journal of Peptides

tab2

Table 2

Table 2: Significant Increase in Salivary Substance P Level after a Single Oral Dose of Cevimeline in Humans 